However, preliminary work in our laboratory suggests a degree of disease specificity: serum MIF is also elevated in European patients with hepatocellular carcinoma (relative to our 29 Japanese non-cancer controls), but is not elevated in patients with lung or pancreas cancer or individuals without cancer (n ⩾ 30 per group, data not shown). Here, MIF is linked to hepatocellular carcinoma.